Defi cient nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signaling results from endothelial dysfunction and may underlie impaired cardiac relaxation in patients with heart failure with preserved left ventricular ejection fraction (HFpEF) and pulmonary hypertension (PH). Th e acute hemodynamic eff ects of riociguat, a novel soluble guanylate cyclase stimulator, were characterized in patients with PH and HFpEF.
Approximately 30% to 50% of patients with heart failure (HF) have a preserved left ventricular ejection fraction (HFpEF), a condition associated with dismal prognosis 1 and for which there are still no proven therapies to improve outcomes. 2 Several pathophysiologic mechanisms have been demonstrated in HFpEF, including left ventricular (LV) diastolic dysfunction, 3 arterial stiff ening, and abnormalities of LV-arterial coupling, 4, 5 which may compromise LV energetic effi ciency. With longstanding pulmonary venous congestion, the majority of patients with HFpEF develop increased pulmonary arterial pressures and pulmonary hypertension (PH). PH has been shown to be a major determinant of mortality in this population and represents a potential novel therapeutic target in HFpEF. 6, 7 HF-and PH-related diseases are characterized by endothelial dysfunction. [8] [9] [10] [11] [12] Preclinical and small clinical studies suggest that defi cient nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling is involved in impaired cardiac relaxation/distensibility. 13 Furthermore, low cyclic guanosine monophosphate (cGMP) levels in myocardial tissue may underlie abnormal cardiomyocyte function. 14 Th us, targeting the NO-sGC-cGMP signaling pathway may be a promising approach for the treatment of HFpEF with PH.
Riociguat is a novel soluble guanylate cyclase (sGC) stimulator 15 with a dual mode of action, sensitizing sGC to endogenous nitric oxide (NO) and directly stimulating sGC independent of NO. 16 Riociguat induces vasodilation and has antifi brotic, antiproliferative, and antiinfl ammatory eff ects. [15] [16] [17] [18] In clinical studies, riociguat has proven effi cacy in pulmonary arterial hypertension and chronic thromboembolic PH. 19, 20 In a randomized, placebo-controlled phase 2b study in patients with HF and PH due to systolic LV dysfunction (Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial [LEPHT]), riociguat was well tolerated and improved cardiac index, pulmonary (PVR) and systemic vascular resistance (SVR), as well as quality of life, without signifi cantly changing mean pulmonary artery pressure (mPAP, primary end point) or systolic BP. 21 In the current study (Acute Hemodynamic Eff ects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure [DILATE-1]), we aimed to characterize the hemodynamic eff ects, safety, and pharmacokinetics of single oral doses of riociguat in patients with HFpEF and PH.
Materials and Methods

Study Design
DILATE-1 (clinicaltrials.gov: NCT01172756) was a double-blind, randomized, placebo-controlled, parallel-group phase 2a study conducted in fi ve centers across Austria, the Czech Republic, and Germany. Patients received oral placebo or riociguat 0.5 mg, 1 mg, or 2 mg in three subsequent ascending dose cohorts. 
Patient Population
Eligible patients were those aged Ն 18 years with symptomatic HFpEF and PH despite optimized therapy with a stable dose of standard medication for the control of symptoms and risk factors for . 30 days ( Ն 7 days for diuretic therapy). Detailed inclusion and exclusion criteria are provided in e-Appendix 1.
Study Procedures
Right-sided heart catheterization was performed by insertion of a balloon-tipped pulmonary artery thermodilution catheter via the right internal jugular vein. Hemodynamic and echocardiographic parameters were recorded at regular intervals up to 6 h aft er intake of study drug. Blood samples for pharmacokinetics and exploratory biomarkers were taken at regular intervals up to 24 h after intake of study drug. Safety was assessed via unblinded data review by an independent datamonitoring committee. Additional safety follow-ups occurred on days 14 and 30 aft er study drug administration.
Outcome Measures
Th e primary effi cacy variable was the peak decrease from baseline in mPAP, defi ned as the largest mPAP change from baseline up to 6 h aft er study drug administration. Secondary variables included additional hemodynamic and echocardiographic parameters, biomarker levels, safety variables, and pharmacokinetics. For the secondary hemodynamic and echocardiographic variables, the mean change from baseline of all evaluations up to 6 h after study drug administration was calculated. Safety was assessed by adverse events (AEs), vital signs, and laboratory evaluations, as defi ned in e-Appendix 1 .
Post hoc exploratory estimation of myocardial oxygen consumption (MVO 2 ) was carried out as defined in e-Appendix 1 . All patients who completed hemodynamic assessment were eligible for pharmacokinetic analysis. Details of pharmacokinetic analysis are provided in e-Appendix 1 .
Statistical Analysis
Statistical analyses were performed using Statistical Analysis System (SAS Institute Inc). Th e analysis of effi cacy was performed in patients valid for per-protocol analysis. Th e primary variable was assessed using a two-group, two-sided t test on the riociguat 2 mg group vs placebo at the .05 signifi cance level.
Exploratory analysis of the secondary effi cacy and post hoc variables was via analysis of variance, with treatment and time aft er study drug administration as main eff ects and a treatment by time interaction. Th is was followed by sequential pairwise comparisons between the three riociguat doses and placebo based on least squares means. AEs were analyzed descriptively in the safety population (all randomized patients). All values displayed are means Ϯ SD unless stated otherwise.
Results
Demographic Data
Of the 46 patients screened, 39 were eligible for study participation and 36 completed all study examinations ( Fig 1 ) . Demographic and clinical characteristics are shown in Table 1 . A high proportion of patients had comorbidities typical of HFpEF, including history of atrial fi brillation (AF) (69%), AF at baseline (44%), diabetes mellitus (44%), coronary artery disease (17%), and COPD (19%). Th e majority of patients received antihypertensive and diuretic therapy during the study: 47% angiotensin-converting enzyme inhibitors, 36% angiotensin II receptor antagonists, 44% aldosterone antagonists, 81% b -blockers, and 67% loop diuretics ( Table 2 ) .
Hemodynamics
Hemodynamic parameters at baseline are provided in Table 3 . Th ere was no signifi cant change in the primary variable-peak decrease in mPAP from baseline up to 6 h aft er study drug administration-in the riociguat 2 mg group vs placebo group ( P 5 .6) ( Figs 2, 3 , e- Table 1 ). However, stroke volume (SV) ( P 5 .04) and cardiac index ( P 5 .001) were signifi cantly increased in the riociguat 2 mg group compared with the placebo group, in the absence of increases in pulmonary arterial wedge pressure (PAWP) ( P 5 .9) and signifi cant changes in heart rate (HR) ( P 5 .5) ( Fig 3 , Table 3 ). In parallel, SVR ( P , .05), mean arterial pressure (MAP) ( P 5 .04), and systolic BP ( P 5 .03) significantly decreased in the riociguat 2 mg group vs placebo ( Fig 3 , Table 3 ) without signifi cant changes in transpulmonary pressure gradient (TPG) and PVR. Within-group changes in secondary hemodynamic parameters are provided in e- Table 2 . All hemodynamic changes occurred without an increase in the estimated MVO 2 (mean decrease: 2 0.1 mL oxygen [O 2 ]/min/100 g) ( e- Table 3 ). 22 Although the prospective randomized design minimized baseline imbalances, some diff erences were evident owing to the small sample size. Following adjustment for baseline diff erences between groups, changes in SV, SV index, SVR, cardiac output (CO), cardiac index, diastolic BP, and MAP remained signifi cantly diff erent from placebo in the riociguat 2 mg group ( e-Table 4 ), whereas change in systolic BP did not signifi cantly diff er from the placebo group in this analysis. Table 5 ).
Exploratory Biomarkers and Pharmacokinetics
Plasma N-terminal prohormone of brain natriuretic peptide, asymmetric dimethylarginine, ST2, and galectin-3 revealed no diff erences in changes from baseline upon administration of riociguat compared with placebo ( e- Table 6 ). Following single-dose administration of riociguat, plasma concentrations dose-dependently increased across the three active treatment groups ( e -Fig 1 ) . Peak plasma concentrations of riociguat were reached aft er a median of 1.9 to 2.5 h, and half-life was 13.1 to 14.3 h ( e- Table 7 ).
Safety and Tolerability
Details of AEs during the study are provided in Table 4 ; the majority of AEs were of mild or moderate intensity. Drug-related serious AEs were reported by two placebo group patients (15%) (two cases of decreased CO) and three patients (30%) taking riociguat 2 mg (one case of decreased CO and three cases of decreased MAP).
Regarding AEs of special interest, a fall in invasively measured systemic systolic arterial BP , 80 mm Hg or in invasively measured MAP , 60 mm Hg was reported by one patient (8%) taking placebo, one patient (13%) taking riociguat 1 mg, and three patients (30%) taking riociguat 2 mg. Two patients (15%) taking placebo and one patient (10%) taking riociguat 2 mg experienced a decrease in CO Ն 20% of baseline. One patient (13%) taking riociguat 0.5 mg developed pulmonary edema, which was considered unrelated to study drug by the investigator. One patient (10%) in the riociguat 2 mg group experienced syncope 6 days aft er study drug; the AE was reported during the 30-day follow-up period and was associated with additional intake of sildenafi l.
In the safety population, changes from baseline in arterial O 2 saturation between 30 min and 6 h aft er administration of riociguat were 2 0.2 to 1 0.7% in the placebo group, 2 0.2 to 2 1.7% in the riociguat 0.5 mg group, 2 0.4 to 1 0.8% in the 1 mg group, and 2 1.0 to 2 2.1% in the 2 mg group.
Th ere was one death (13%) in the riociguat 1 mg group. Th e patient died because of pulmonary hemorrhage, which was a complication of the protocol-required right-sided heart catheterization.
Th ere were no clinically relevant changes in vital signs, ECG, or any laboratory variables. A single patient (10%) in the riociguat 2 mg group with a history of paroxysmal AF had AF 24 h aft er drug intake. The mean changes from baseline of all evaluations up to 6 h after study drug administration are shown. ] (continued)
Figure 2 -Peak decrease in mPAP from baseline up to 6 h aft er administration of study drug in the riociguat 2 mg group vs placebo group (primary end point). Th e diff erence between treatment groups was analyzed by a two-group, two-sided t test. Th e treatment diff erence (95% CI) and
P value are also shown. mPAP 5 mean pulmonary artery pressure.
Discussion
Th e acute hemodynamic and echocardiographic eff ects of single doses of riociguat were investigated in patients with HFpEF and PH. Despite no signifi cant change in the primary end point-peak decrease in mPAP-favorable hemodynamic eff ects were observed in the riociguat 2 mg group compared with placebo. Riociguat significantly increased SV and cardiac index, and signifi cantly decreased systolic BP, SVR, and RVED area, without changing HR, PAWP, TPG, or PVR. Riociguat was well tolerated in combination with stable HF therapy.
Riociguat did not have the hypothesized eff ect-reduction in mPAP-in the current study in patients with HFpEF and PH, which was representative of an elderly, predominantly female HFpEF population with elevated PAWP and common comorbidities. As pulmonary selective vasodilators have been reported to worsen leftsided heart fi lling pressures and induce pulmonary edema in patients with PH due to HFpEF, 25, 26 the significant increase in fl ow without an increase in PAWP might be refl ective of the systemic eff ects of riociguat. Although the contribution of aft erload-independent direct myocardial eff ects to this hemodynamic response was not addressed in the current study, the potential of direct sGC stimulators in HFpEF might go beyond hemodynamic eff ects and additionally, or even predominantly, rely on nonhemodynamic eff ects of sGC-derived cGMP signaling in a variety of tissues, including cardiac myocytes. 27 Th e increase in SV was accompanied by a reduction in the size of the right ventricle. Experimental evidence suggests an essential role for sGC activity in loadindependent myocardial relaxation. 28 An alternative or additional explanation could be a decrease in mitral regurgitant volume as a consequence of reduced LV aft erload. A positive inotropic eff ect of riociguat is less likely, given the unaltered ventricular fi lling pressures. Furthermore, preclinical data suggest that sGC stimulation does not increase cyclic adenosine monophosphate production despite signifi cant cGMP increases and may blunt the inotropic response to adrenergic stimulation. 29, 30 Previous attempts to target the NO-sGC-cGMP pathway in HFpEF have shown confl icting results. Despite being widely used as adjunctive therapies in HF, NO donors and organic nitrates are limited by the development of tolerance, oxidative stress, augmentation of endothelial dysfunction, and venoselectivity. 31 Th e hemodynamic response presented here is in agreement with the increase in cardiac index with 16 weeks' riociguat in the LEPHT. 21 By contrast, patients with HFpEF were fourfold more likely than those with HF with reduced ejection fraction to experience a reduction in SV with acute IV nitroprusside, suggesting greater vulnerability of patients with HFpEF to preload reduction. 32 As venodilator eff ects were suggested to play an important role in reducing LV fi lling pressures with nitroprusside, 32 the signifi cant increase in SV with riociguat could potentially be explained by a diff erent regional vasoactivity, which may increase cGMP in the heart and arteries with less of the tolerabilitylimiting preload reduction of NO donors. Despite 30% of patients experiencing a decrease in invasively measured systemic systolic arterial BP , 80 mm Hg or invasively measured systemic mean arterial BP , 60 mm Hg following single doses of riociguat 2 mg, many patients did not have signifi cant signs and symptoms of hypotension. Nevertheless, as the extent of systemic BP reduction with ad hoc dosing of riociguat 2 mg may be more appropriate in patients with higher baseline BP, riociguat should, like angiotensin-converting enzyme inhibitors, be started at low doses and up-titrated in future longerterm studies. Dosing should be handled similar to the LEPHT in patients with HF and reduced ejection fraction. 21 In single-center clinical studies in HFpEF, sildenafi l improved pulmonary artery pressure and right-sided heart function . 33 However, sildenafi l failed to improve peak O 2 consumption in the Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) study and showed no signifi cant benefi t vs placebo in a range of secondary end points in patients with HFpEF. 34 Moreover, subgroup analysis showed no improvement in peak O 2 consumption in patients with higher pulmonary artery systolic pressure (median pulmonary artery systolic pressure was 41 mm Hg [range, 32-51 mm Hg] in the treatment group). In contrast to the signifi cant reduction of SVR observed in the present study, and with chronic riociguat therapy in the LEPHT, 21 SVR was unchanged aft er 6 months of treatment with sildenafi l. 34 Th e RELAX investigators speculated that the ability of phosphodiesterase-5 inhibitors to enhance cGMP might be limited by insuffi cient endogenous stimulation of sGC secondary to reduced NO bioavailability in HFpEF. Th e results of the present study are, therefore, promising regarding the effi cacy of direct, NO-independent sGC stimulation in patients with HFpEF. 35 Th e main limitation of this single-dose study was the relatively small number of patients in each treatment group, which prevented analysis of subgroups of particular interest (eg, high vs low TPG, AF vs sinus rhythm). Th e number of patients with diastolic pressure gradient (DPG) Ն 7 mm Hg was fi ve of 36, thus precluding a valid statistical evaluation of this subgroup. Assessment of riociguat in patients with combined precapillary and postcapillary PH (PAWP . 15 mm Hg, DPG Ն 7 mm Hg), as opposed to isolated postcapillary PH (PAWP . 15 mm Hg, DPG , 7 mm Hg), 36 could be considered for future studies to explore treatment benefi ts in this population.
Baseline diff erences between groups included higher rates of AF at baseline in the riociguat 2 mg group compared with placebo and higher LV end-diastolic volume, SV, LA area, and right ventricular area in riociguat groups than in placebo. Th us, an infl uence of the extent of remodeling and structural changes on the observed results cannot be excluded.
Th e presence of patients with AF in the DILATE study may have aff ected the accuracy of hemodynamic measurements. However, this limitation was minimized by the study protocol recommending that investigators use an average of fi ve measurements during thermodilution in patients with AF vs three for those in sinus rhythm.
Hemodynamic tracings and echocardiography were conducted and read on site in accordance with the standards at each institution; only key echocardiographic parameters were measured to allow for adherence to the protocol-defi ned acquisition intervals (as short as 30 min), without processing of results for central assessment by core laboratories. Th e observed changes in fl ow were only assessed by a single method. Th ere was no signifi cant change in mixed venous oxygen saturation, suggesting that the actual change in CO with riociguat was lower than that observed using thermodilution, although direct assessment of oxygen consumption was not performed. Furthermore, there were no studyspecifi c standardization procedures regarding endexpiratory capture and analysis of PAWP at mid-A; local standards defi ned their acquisition.
Finally, the hemodynamic and echocardiographic eff ects of single doses of riociguat in this exploratory phase 2b study cannot be extrapolated to short-term (weeks) or long-term (months to years) treatment responses. Chronic, large-scale, placebo-controlled studies are required, which should include blinded central reading of hemodynamic and echocardiographic measurements.
Conclusions
In conclusion, single doses of riociguat were well tolerated and showed favorable hemodynamic and echocardiographic eff ects in patients with HFpEF and PH. Riociguat 2 mg signifi cantly increased SV and cardiac index, and decreased systolic BP, SVR, and RVED area, without altering HR, TPG, or PVR. Th e ventricular fi lling required to establish an increased SV was not accompanied by increased PAWP, raising the hypothesis that in addition to its systemic vasodilatory eff ect, riociguat could improve diastolic function. Future clinical studies should include the titration of oral sGC stimulators over a longer period of time in patients with HFpEF.
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